|
Aug 8
|
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
|
|
Jul 24
|
Companies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In Growth
|
|
May 13
|
Cardiff Oncology to Present at Upcoming Investor Conferences in May
|
|
May 4
|
Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
|
|
May 2
|
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
|
|
Apr 25
|
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
|
|
Apr 8
|
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
|
|
Mar 6
|
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
|
|
Mar 3
|
Cardiff Oncology Full Year 2023 Earnings: Beats Expectations
|
|
Mar 1
|
Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results
|
|
Feb 29
|
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
|
|
Feb 29
|
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
|
|
Feb 29
|
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
|
|
Feb 26
|
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
|
|
Feb 22
|
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
|
|
Nov 2
|
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
|
|
Sep 26
|
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
|